Search research articles
Contact Us
Filters
Showing results (21-30 of 27) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 27 results.
BMC Cancer
|
October 21, 2016
Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial
Perparim Limani, Michael Linecker, Philipp Kron, et al.
Nature Communications
|
June 22, 2021
Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors
Marcel A Schneider, Michael Linecker, Ralph Fritsch, et al.
Cancer Immunology, Immunotherapy : CII
|
April 6, 2007
NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy
Jean-Philippe Theurillat, Ursina Zürrer-Härdi, Zsuzsanna Varga, et al.
International Journal of Cancer
|
November 29, 2007
Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterparts
Jean-Philippe Theurillat, Ursina Zürrer-Härdi, Zsuzsanna Varga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2004
Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy
Pia Huguenin, Karl T Beer, Abdelkarim Allal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2007
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Richard Herrmann, György Bodoky, Thomas Ruhstaller, et al.
Annals of Surgery
|
August 2, 2021
Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials
Dominique L Birrer, Henriette Golcher, Riccardo Casadei, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 27) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 27 results.
BMC Cancer
|
October 21, 2016
Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial
Perparim Limani, Michael Linecker, Philipp Kron, et al.
Nature Communications
|
June 22, 2021
Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors
Marcel A Schneider, Michael Linecker, Ralph Fritsch, et al.
Cancer Immunology, Immunotherapy : CII
|
April 6, 2007
NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy
Jean-Philippe Theurillat, Ursina Zürrer-Härdi, Zsuzsanna Varga, et al.
International Journal of Cancer
|
November 29, 2007
Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterparts
Jean-Philippe Theurillat, Ursina Zürrer-Härdi, Zsuzsanna Varga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2004
Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy
Pia Huguenin, Karl T Beer, Abdelkarim Allal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2007
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Richard Herrmann, György Bodoky, Thomas Ruhstaller, et al.
Annals of Surgery
|
August 2, 2021
Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials
Dominique L Birrer, Henriette Golcher, Riccardo Casadei, et al.
Page
of 3